中文摘要：

金黄色葡萄球菌是全球院内感染的首要病原菌，临床分离的金葡菌80％以上为耐甲氧西林（MRSA）菌株，因其耐药性，尤其是多重耐药性的快速增长，抗MRSA感染日益成为抗感染治疗的难点和热点。近年来，人们在充分认识金葡菌耐药机制的基础上，积极开发新型抗MRSA药物，取得了长足发展。对MRSA的耐药机制及该机制指导下抗金葡菌药物开发现状作一综述。

英文摘要：

Staphyloccus aureus （SA） is one of the primary pathogenic bacteria in global hospital infections. More than 80% of clinically isolated SA are methieillin-resistant ones （MRSA） , since its medicine resistance, especially the fast growth of multi-drug resistance of SA has made anti-MRSA infection becoming difficulty and hot spot of antiinfection treatment. Recently, based on people＇s full knowledge about the mechanism of SA＇s drug resistance, new medicine of anti-MRSA has been positively developed and got rapid growth. Current development of MRSA drug resistanee mechanism and anti-SA medicine under the guidance of the mechanism of drug resistance was reviewed in this article.